NRX Pharmaceuticals Inc (NASDAQ: NRXP) is 44.55% higher on its value in year-to-date trading and has touched a low of $1.10 and a high of $7.33 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NRXP stock was last observed hovering at around $2.84 in the last trading session, with the day’s gains setting it 0.34%.
Currently trading at $3.18, the stock is -11.17% and 31.07% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.91 million and changing 11.97% at the moment leaves the stock 40.48% off its SMA200. NRXP registered -20.30% loss for a year compared to 6-month gain of 57.43%. The firm has a 50-day simple moving average (SMA 50) of $2.3871 and a 200-day simple moving average (SMA200) of $2.262945.
The stock witnessed a -9.40% loss in the last 1 month and extending the period to 3 months gives it a 140.91%, and is 6.35% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 13.86% over the week and 21.51% over the month.
Fwd P/E is 9.94. Distance from 52-week low is 189.09% and -56.63% from its 52-week high.
The EPS is expected to grow by 53.58% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
21.0 institutions hold shares in NRX Pharmaceuticals Inc (NRXP), with institutional investors hold 7.92% of the company’s shares. The shares outstanding are 15.70M, and float is at 11.95M with Short Float at 10.10%. Institutions hold 6.05% of the Float.
NRX Pharmaceuticals Inc (NRXP) Insider Activity
The most recent transaction is an insider purchase by Javitt Jonathan C, the company’s Chairman and Chief Scientist. SEC filings show that Javitt Jonathan C bought 40,000 shares of the company’s common stock on Dec 17 ’24 at a price of $1.17 per share for a total of $46800.0. Following the purchase, the insider now owns 84634.0 shares.
